Genfleet Therapeutics (Shanghai) Inc.

Zhejiang Genfleet Therapeutics Co., Ltd.

Jiangsu Hengrui Medicine Company Ltd.

Shanghai Hengrui Pharmaceutical Co., Ltd.

Yangtze River Pharmaceutical Group Co., Ltd.

Shanghai Haiyan Pharmaceutical Technology Co., Ltd.

Genfleet Therapeutics Inc.

Jiong Lan

Shuhui Chen

Liang Zhang

Kai Zhang

Haiying He

Yu Wang

Tao Jiang

Yang Liu

Jing Xie

Qiyue Hu

Xiang Chen

Xuejun Zhang

Fusheng Zhou

Zhiyuan Zhang

Dong Huang

Jianbiao Peng

Songliang Wu

Xing Liu

Chong Wen

Yaoping Zhu

Yi Hu

Shuchun Guo

Yunzhou Jin

Xiangyu He

Jinzhu Zhao

Yuhe Wang

Yuan Chen

Fangfang Jin

Qiang Lv

Xiaotao Li

Wan He

Qing Dong

Biao Ma

Bonian Liu

Jing Lei

Ping Bu

Changjiang Qiao

Sida Shen

Chunzhou Han

Chunyan Gu

Lijian Cai

Chonglan Lin

The present invention provides a polymorph of a CDK9 inhibitor and a preparation method for the polymorph and use thereof. Specifically, disclosed are 4-(((4-(5-chloro-2-(((1R,4r)-4-(((R)-1-methoxypropyl-2-yl)amino)cyclohexyl)amino)pyridine-4-yl)thiazole-2-yl)amino)methyl)tetrahydro-2H-pyrano-4-methylnitrile maleate or fumarate or polymorphs thereof and applications thereof. In addition, also disclosed are a pharmaceutical composition containing the substance and an application of the pharmaceutical composition.

Polymorph of CDK9 inhibitor and preparation method for polymorph and use thereof

A substituted heterocyclic fused cyclic compound as represented by formula (I) or formula (IA) and having a selective inhibitory effect on KRAS gene mutation, or a pharmaceutically-acceptable salt, a stereoisomer, a solvate or a prodrug thereof, a pharmaceutical composition containing the compound, and an application thereof in preparation of cancer drugs are provided.

Substituted heterocyclic fused cyclic compound, preparation method therefor and pharmaceutical use thereof

Growing community of inventors

Shanghai, China

Jiong Lan